Trial | NCT02072408  Report issue

Title

Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    46
The purpose of this study is to evaluate the efficacy and safety of aflibercept for treatment of polypoidal choroidal vasculopathy without active polyp.
Study Started
Feb 28
2014
Primary Completion
Nov 02
2017
Study Completion
Nov 02
2017
Last Update
Sep 05
2018

Drug aflibercept

Three monthly intravitreal aflibercept (2mg) injections Five bimonthly intravitreal aflibercept (2mg) injections Rescue treatment: Verteporfin photodynamic therapy Loss of five ETDRS letters or one Snellen line of vision from baseline Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection Presence of active polyp on indocyanine green angiography

polypoidal choroidal vasculopathy without polyp Experimental

Criteria 

Inclusion Criteria:

polypoidal choroidal vasculopathy without active polyp
decreased visual acuity by subretinal fluid and hemorrhage involving foveal center

Exclusion Criteria:

polypoidal choroidal vasculopathy with active polyp
previous photodynamic therapy more than three times
anti-VEGF injection within one month
photodynamic therapy or intraocular steroid treatment within three months
No Results Posted